Having found that in biomedical research, the Bird Rock resident and scientist at La Jolla’s Sanford Burnham Prebys has ...

Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.

Myotonic dystrophy type 1 (DM1), a genetic disorder, shares overlapping features with chronic kidney disease, including ...

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, will present data from the Phase 1/2 INSPIRE DUCHENNE ...

Roland Beres sits down with April Gannon of the Muscular Dystrophy Association to discuss the importance of raising money and ...

Look ahead to this year's Muscular Dystrophy Association (MDA) meeting, which will feature discussions on the latest gene therapies, clinical trial data, policy considerations, and more in the realm ...

A new discovery about how tiny protein clusters form in cells could pave the way for treatments for Emery-Dreifuss muscular ...

BMO Capital Markets initiates coverage on Dyne Therapeutics with an Outperform rating, an $84 target, and a projected $4.3 billion peak sales for DYNE-101.

Researchers combined advanced imaging techniques and theoretical physics to observe and explain how nanoclusters of the protein emerin form inside living cells. The study uncovers the molecular 'rules ...

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on sevasemten, an investigational orally ...

Dominic Olsen is a bright and determined 10-year-old boy living with Duchenne Muscular Dystrophy, a rare disease that has ...

including Duchenne muscular dystrophy (Duchenne), Friedreich’s ataxia (FA), catecholaminergic polymorphic ventricular tachycardia (CPVT), TNNT2-mediated dilated cardiomyopathy, BAG3-mediated ...